These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 7407769

  • 21. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
    O'Connell MJ, Moertel CG, Rubin J, Hahn RG, Kvols LK, Schutt AJ.
    J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.
    Hart RD, Ohnuma T, Holland JF.
    Cancer Treat Rep; 1980 Oct; 64(4-5):617-24. PubMed ID: 6448687
    [Abstract] [Full Text] [Related]

  • 24. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
    Kleeberg UR, Mulder JH, Rümke P, Thomas D, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
    [Abstract] [Full Text] [Related]

  • 25. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
    Chiuten DF, Miller A, Valdivieso M, Loo TL, Bedikian A, Bodey GP, Benvenuto JA, Freireich EJ.
    Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
    [Abstract] [Full Text] [Related]

  • 26. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
    Creagan ET, Ahmann DL, Ingle JN, Purvis JD, Green SJ.
    Cancer Treat Rep; 1981 Aug; 65(1-2):169. PubMed ID: 6894400
    [No Abstract] [Full Text] [Related]

  • 27. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Klaassen DJ, Laurie JA.
    J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
    [Abstract] [Full Text] [Related]

  • 28. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
    Karle JM, Anderson LW, Erlichman C, Cysyk RL.
    Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
    [Abstract] [Full Text] [Related]

  • 29. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES, Vale K, Williams LJ, Martin DS, Young CW.
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [Abstract] [Full Text] [Related]

  • 30. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI, Oster W, Kerr DJ, Canney PA, Yosef H, Steward WP, Kaye SB, Cassidy J.
    Eur J Cancer; 1994 May; 30A(7):950-5. PubMed ID: 7946590
    [Abstract] [Full Text] [Related]

  • 31. Phase II study of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study.
    Ettinger DS, Tritchler D, Earhart R, Creech RH.
    Cancer Treat Rep; 1984 Oct; 68(10):1297-8. PubMed ID: 6525602
    [No Abstract] [Full Text] [Related]

  • 32. A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
    Rubin J, Schutt AJ, O'Connell MJ, Gertz MA, Moertel CG.
    Am J Clin Oncol; 1984 Oct; 7(5):523-5. PubMed ID: 6507373
    [Abstract] [Full Text] [Related]

  • 33. Response of psoriasis to N-phosphonacetyl-L-aspartate.
    Earhart RH, DeConti RC, Rubin J, Ohnuma T.
    Lancet; 1981 Jun 06; 1(8232):1257-8. PubMed ID: 6112581
    [No Abstract] [Full Text] [Related]

  • 34. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET, O'Connell MJ, Kovach JS.
    Cancer; 1983 Aug 15; 52(4):615-8. PubMed ID: 6861099
    [Abstract] [Full Text] [Related]

  • 35. Phase I trial of combination therapy with PALA and 5-FU.
    Meshad MW, Ervin TJ, Kufe D, Johnson RK, Blum RH, Frei E.
    Cancer Treat Rep; 1981 Aug 15; 65(3-4):331-4. PubMed ID: 6263472
    [Abstract] [Full Text] [Related]

  • 36. PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
    Muss HB, Bundy B, DiSaia PJ, Stehman FB, Beecham J.
    Am J Clin Oncol; 1984 Dec 15; 7(6):741-4. PubMed ID: 6528869
    [Abstract] [Full Text] [Related]

  • 37. Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
    O'Connell MJ, Rubin J, Schutt AJ, Moertel CG, Kvols LK.
    Cancer Treat Rep; 1983 Dec 15; 67(12):1141-2. PubMed ID: 6360350
    [No Abstract] [Full Text] [Related]

  • 38. [Chemotherapy of metastasizing cancers of the colon and rectum].
    Piedbois P, Lévy E, Le Bourgeois JP, Buyse M.
    Ann Chir; 1993 Dec 15; 47(6):480-3. PubMed ID: 7692804
    [No Abstract] [Full Text] [Related]

  • 39. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA, Rouini MR, Cripps MC, Shirazi FH, Veerasinghan S, Molepo JM, Obrocea M, Redmond D, Bates S, Fry D, Stewart DJ, Goel R.
    Oncol Rep; 1998 Dec 15; 5(1):217-21. PubMed ID: 9458325
    [Abstract] [Full Text] [Related]

  • 40. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
    Paridaens R, Mouridsen HT, Palshof T, Cocconi G, Van Oosterom A, Rotmensz N, Sylvester R, Heuson JC, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Jan 15; 18(1):67-70. PubMed ID: 6211361
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.